

Renal Services

Basiliximab (Simulect®): Information for kidney transplant patients

What is Basiliximab (Simulect®) used for?

Basiliximab (Simulect®) is an immunosuppressant medicine. It helps prevent rejection of your kidney transplant.

How does Basiliximab (Simulect®) work?

Basiliximab (Simulect®) works by stopping your body's production of cells that are part of your immune system. This controls your immune system to stop rejection of your new kidney.

How to take Basiliximab (Simulect®)

You will be given two doses of 20mg as an injection by a nurse. One dose is given on the day of your transplant operation and one dose 4 days later. You will not need any further doses.

Side effects

There are no specific side effects with basiliximab (Simulect®). People can have allergy type reactions, but this is very rare.



Important: long-term effects

You are taking immunosuppressant medicines. This means that you may experience long-term health effects. Long-term health effects include increased risks of infection and cancer.

It is important that you follow the transplant team's health advice. Please read the booklet that they give you. It provides important information that you need.

Please tell your doctor, nurse, or pharmacist if you think you have been given Basiliximab (Simulect®) before, or if you have had a previous transplant. Your doctor will decide if you need any further doses as this may increase your risk of developing an allergy type reaction.

The Trust has access to interpreting and translation services. If you need this information in another language or format, please contact 024 7696 7777 and we will do our best to meet your needs.

The Trust operates a smoke free policy.

Did we get it right?

We would like you to tell us what you think about our services. This helps us make further improvements and recognise members of staff who provide a good service.



Have your say. Scan the QR code or visit:
www.uhcw.nhs.uk/feedback

Document History

Department:	Renal Services
Contact:	26785
Updated:	November 2023
Review:	November 2025
Version:	4.2
Reference:	HIC/LFT/1537/12